Crohn's disease is associated with low bone mineral density and altered bone metabolism.
A research team from Belgium undertook a study into bone metabolism in Crohn's disease patients treated with infliximab.
The researchers studied 71 Crohn's disease patients who had been treated for the first time with infliximab for refractory Crohn's disease.
The research group measured serum biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) before and 8 weeks after infliximab therapy.
| Infliximab therapy may rapidly influence bone metabolism by acting either on bone formation or bone resorption"|
|Alimentary Pharmacology and Therapeutics|
The researchers then compared these values with values obtained from a matched healthy control group.
The team found that eight weeks after treatment with infliximab, there was a normalization of bone markers.
There was a median increase in formation markers of 14-51% and a lower but significant decrease in resorption marker (median 11%).
The researchers noted a clinically relevant increase in bone formation markers in 30-61% of patients according to the marker.
In addition, there was a clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients.
The researchers found no association with any tested demographic or clinical parameter.
Dr Louis commented, "Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption".
He added, "This improvement seems to be independent of clinical response to infliximab."